At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 118 enrolled
Drug / intervention
Fluarix™/Influsplit SSW®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in People Aged 18 Years or Above
In Brief
A Phase 3 clinical trial evaluating Fluarix™/Influsplit SSW® for Influenza. Completed, enrolled 118 participants across 5 sites.
Detailed Summary
This study is designed to test the immunogenicity and reactogenicity of the FluarixTM/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2009-2010 season.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartJun 2009
Primary CompletionJul 2009
TodayJul 2026
First PostedJun 15, 2009
Enrollment StartJun 16, 2009
Primary CompletionJul 8, 2009
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 17.0 years ago
Interventions
Fluarix™/Influsplit SSW®biological
single intramuscular dose on Day 0